Celldex Stock Falls On Unusually High Volume (CLDX)

NEW YORK ( TheStreet) -- Celldex Therapeutics (Nasdaq: CLDX) is trading at unusually high volume Monday with 3.3 million shares changing hands. It is currently at two times its average daily volume and trading down 83 cents (-3.9%) at $20.44 as of 11:45 a.m. ET.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Celldex has a market cap of $1.51 billion and is part of the health care sector and drugs industry. Shares are up 217% year to date as of the close of trading on Friday.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States.

TheStreet Ratings rates Celldex as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow. You can view the full Celldex Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Is Strong On High Volume Today